日本人における血中PCSK9濃度と冠動脈疾患の関連性 by 野瀬 大補
 1 
 
 
 
 
 
Association between plasma levels of PCSK9 and the presence of coronary artery 
disease in Japanese 
 
Daisuke Nose, MDa, Yuhei Shiga, MD, PhDa, Yoko Ueda, MD, PhDa, Yoshiaki Idemoto, MD, PhDa, 
Kohei Tashiro, MDa, Yasusnori Suematsu, MD, PhDa, Takashi Kuwano, MD, PhDa, Ken Kitajima, 
MD, PhDa, Keijiro Saku, MD, PhDa,b, Shin-ichiro Miura, MD, PhD a,b,*. 
 
a Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan; b Department 
of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan. 
 
 
 
Running head: PCSK9 and coronary artery disease 
*Corresponding author: Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 
Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. 
Tel: (+81) 92-801-1011; Fax: (+81) 92-865-2692. 
 E-mail address: miuras@cis.fukuoka-u.ac.jp (S. Miura) 
最終的な出版論文は以下のサイトを通じて Springer社から入手可能です  
https://link.springer.com/article/10.1007/s00380-018-1218-1 
 2 
 
Abstract 
The ability of pro-protein convertase subtilisin/kexin type 9 (PCSK9) levels to predict the presence 
or severity of coronary artery disease (CAD) remains controversial. The purpose of this study was to 
investigate these associations. We enrolled 393 patients who were clinically suspected to have CAD 
or who had at least one cardiac risk factor and underwent multidetector row computed tomography 
coronary angiography. The presence of CAD (≥ 50 % coronary stenosis), the number of significantly 
stenosed coronary vessels, and plasma levels of PCSK9 by ELISA were analyzed. Plasma PCSK9 
levels (log-transformed data) were significantly associated with the presence of CAD. Next, we 
divided the patients into two groups (non-statin and statin groups) according to statin treatment. 
PCSK9 levels in the non-statin group were significantly lower than those in the statin group. There 
were no significant differences in PCSK9 levels between the absence and presence of CAD in the 
statin group. However, in the non-statin group, PCSK9 levels in patients with CAD were 
significantly higher than those in patients without CAD. PCSK9 levels, in addition to age, gender, 
BMI, DM and HDL-C, were independently associated with the presence of CAD by a multivariable 
analysis. In conclusion, our results demonstrated that plasma PCSK9 levels may be a marker for 
evaluating the presence of CAD. 
Key words: pro-protein convertase subtilisin/kexin type 9; coronary artery disease; multidetector 
row computed tomography; statin.   
 3 
 
Introduction 
Pro-protein convertase subtilisin kexin-9 (PCSK9) is a protein that regulates the expression of low-
density lipoprotein (LDL) receptors [1]. PCSK9 levels also seem to play a role in regulating the 
concentrations of apo B and TG, in addition to LDL cholesterol (LDL-C) [2-4]. However, this latter 
association with LDL-C is abolished by treatment with statin [5]. Recent meta-analyses have shown 
that PCSK9 levels might be affected by the dose and type of statin [6, 7]. Genetic studies on gain-of-
function or loss-of-function mutations in PCSK9 showed that PCSK9 is associated with the risk of 
coronary artery disease (CAD) [8, 9]. Several studies have suggested that PCSK9 levels were 
associated with the degree of coronary stenosis, and might be a biomarker of CAD [10-12]. On the 
other hand, Zhu et al. argued that PCSK9 was unlikely to be a biomarker of atherosclerotic risk or 
vascular health [13]. Some equivocal reports on these relations have been reported, and this issue 
remains controversial [13-15]. 
Previous reports that supported the hypothesis of a positive relation included many subjects with 
severe CAD assessed by Gensini scores, and showed significant differences between the group with 
high scores and other groups [10, 12]. To date, several studies have indicated that the risk factors and 
background for CAD were significantly different among different ethnic groups, and it is unlikely 
that biomarkers can be generalized to other ethnicities [16, 17]. In particular, Japanese show a unique 
association between the lipid profile and the development of CAD [18]. 
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The present study aimed to examine whether PCSK9 levels are useful for predicting the 
presence and severity of CAD in Japanese, by using multi detector-row computed tomography 
coronary angiography (CCTA). 
 
Methods 
Study subjects 
Patients were identified and recruited through a review of the CCTA database of Fukuoka University 
between April 2012 and July 2014. From among 424 consecutive patients, 31 lacked some data, and 
thus 393 were enrolled. Inclusion criteria were as follows: clinically suspected of having CAD based 
on abnormal findings by electrocardiography and ⁄or chest symptoms, or with at least one 
cardiovascular risk factor, and age > 20. Patients with acute coronary syndrome, a history of known 
CAD (prior myocardial infarction, prior coronary intervention, or coronary artery bypass grafting), 
severe renal insufficiency [estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73m2], and 
missing data were excluded. The study was conducted as a single-center, cross sectional analysis. 
The study complied with the Declaration of Helsinki and was approved by the Independent Review 
Board (IRB) of Fukuoka University Hospital (Fukuoka University Hospital EC/IRB: #09-10-02). All 
patients provided their written informed consent to participate before blood sampling and CCTA. 
The study is registered with the University Hospital Medical Information Network 
(UMIN000016641). 
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Evaluation of coronary stenosis using CCTA 
All patients were scanned by CCTA as previously described [19]. The use and dose of beta-blocker 
was left to the physician’s discretion, according to the baseline heart rate and body weight. All 
segments were assessed according to the 15-segment American Heart Association coronary artery 
model [20]. Significant coronary artery stenosis was defined as narrowing of the coronary lumen ≥ 
50% using multiplanar reconstructions or cross-sectional images. Subjects were classified into 3 
groups [0, single (1), and multi (2+3) vessel disease (VD) groups] according to the number of 
coronary stenosed vessels. CCTA was assessed by trained cardiologists using Ziostation (Ziosoft 
Inc., Tokyo, Japan), a computed tomography workstation. These cardiologists were blinded to the 
clinical characteristics and the blood tests. These cardiologists were blinded to the clinical 
characteristics and the blood tests. Overall, the severity of CAD was assessed according to the 
number of VD and the Gensini score. This scoring system was established to define the severity of 
coronary stenosis. The details have been reported elsewhere [21]. Coronary artery calcium score was 
assessed by using the Agatson score. 
 
Evaluation of CAD risk factors 
In all subjects, age, gender, body mass index (BMI), systolic blood pressure, diastolic blood pressure, 
serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-
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C), LDL-C, uric acid (UA), blood glucose, hemoglobin A1c (HbA1c), smoking (current and past 
smokers), family history [myocardial infarction, angina pectoris or sudden death] and medication use 
were evaluated as cardiovascular risk factors by cardiologists. These cardiologists were blinded to 
the CCTA results and all clinical information. Concentrations of TC, TG, HDL-C, LDL-C and UA 
were measured by enzymatic methods. Plasma levels of PCSK9 were measured using a commercial 
sandwich enzyme immunoassay (R&D Systems, Minneapolis, MN) according to the manufacturer’s 
instructions. BMI was calculated as weight (kg)/height (m)2. Patients who had a current SBP ≥ 140 
mmHg and/or DBP ≥ 90 mmHg or who were receiving anti-hypertensive therapy were considered to 
have hypertension (HTN). Patients with LDL-C ≥ 140 mg/dl, TG ≥ 150 mg/dl, and/or HDL-C < 40 
mg/dl, or who were being treated with lipid-lowering therapy were defined as DL. The HbA1c value 
was evaluated according to the National Glycohemoglobin Standardization Program. Patients were 
considered to have diabetes mellitus (DM) if they satisfied any of the diagnostic criteria defined by 
the Japan Diabetes Society [fasting blood sugar level ≥ 126 mg/dL, 2-hour 75g OGTT glucose level 
≥ 200 mg/dL or random blood sugar level ≥ 200 mg/dL (venous plasma levels), or if they were 
taking glucose-lowering drugs with a clear diagnosis]. The National Kidney Foundation has defined 
chronic kidney disease (CKD) as a GFR of less than 60 ml/min/1.73 m2 [22]. Estimated glomerular 
filtration rate (eGFR) was determined using the abbreviated equation as modified for Japanese by the 
Japanese Society of Nephrology; 194 × [age (years)]-0.287 × [serum Cr (mg/dl)] -1.094 × 
[0.739 if female]. CKD was defined as an eGFR level < 60 ml/min/1.73 m2 [23]. 
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Statistical analysis 
All calculations were performed with the statistical software JMP® 13 (SAS Institute Inc., Cary, NC, 
USA). Continuous data are reported as mean ± standard deviation (SD) or as median values (inter-
quartile range). Categorical and continuous variables were compared between the groups by the t-test 
or Mann-Whitney U-test, respectively. When continuous variables did not show a normal 
distribution, expressed as a median value and inter-quartile range, we used the Wilcoxon rank-sum 
test. The Spearman rank correlation coefficient was used to evaluate associations between the 
groups. Log-normalization was used for PCSK9 levels, which were not normally distributed. 
Changes in quantitative results of PCSK9 between no- or 1VD and 2+3VD were determined by one-
way ANOVA with a multiple comparison Tukey-Kramer HSD test, or Kruskal-Wallis test with the 
Steel-Dwass test where appropriate. A multivariable analysis was performed using a logistic 
regression analysis for independent variables (age, gender, family history, BMI, smoking, HTN, DM, 
DL, CKD, statin treatment, HDL-C, LDL-C in addition to PCSK9 levels) that were related to the 
presence or absence of CAD. A value of p < 0.05 was considered significant. 
 
Results 
Patient characteristics in all patients and the non-CAD and CAD groups 
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Table 1 shows the clinical characteristics in all patients, and the non-CAD and CAD groups. Among 
all patients, the median age was 66 years, 51 % of patients were male and 34 % were treated with 
statins. The patients with CAD were older and had a higher prevalence of DM, HTN, and CKD. The 
use of angiotensin II receptor blocker, calcium channel blocker (CCB), beta-blocker (BB), 
sulfonylurea, and statin were significantly higher in the CAD group. 
 
Patient characteristics in all patients, and in patients with non-CAD and CAD in the non-statin 
and statin groups. 
Table 2 shows the clinical characteristics of all patients and patients with non-CAD and CAD in the 
non-statin and statin groups. The patients treated with statin had significantly lower levels of LDL-C, 
and their morbidity percentages of CAD, DM, and HTN, but not DL, were also higher than those in 
patients without statin (Supplementary Table). Second, patients with statin and non-statin treatment 
were further divided into two groups: CAD and non-CAD groups. In the non-statin group, patients 
with CAD were significantly older, included more smokers and CKD, and had higher levels of serum 
HbA1c and lower levels of HDL-C than those without CAD. In the non-statin and statin groups, 
patients with CAD had a higher percentage of HTN than those without CAD. With regard to 
medications, anti-hypertensive drugs in the statin group were significantly higher than those in the 
non-statin group. In the non-statin group, patients with CAD had a higher percentage of CCB, while 
in the statin group, they had a higher percentage of BB.   
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Levels of PCSK9 in all patients and the non-CAD and CAD groups.  
In all patients, PCSK9 levels (log-transformed data) in the CAD group were significantly higher than 
those in the non-CAD group (5.40 ± 0.33 vs. 5.29 ± 0.39, p = 0.004, Table 1 and Figure 1A). In 
addition, in all patients, PCSK9 levels in the statin group were significantly higher than those in the 
non-statin group (5.49 ± 0.37 vs. 5.28 ± 0.34, p < 0.01, Table 2 and Figure 1A). In the non-statin 
group, patients with CAD showed significantly higher PCSK9 levels than those without CAD (5.35 
± 0.31 vs. 5.21 ± 0.36, p = 0.0008) (Table 2 and Figure 1B), although there was no significant 
difference between the CAD and non-CAD groups in the statin group (Table 2 and Figure 1C). 
  To examine the association between PCSK9 levels and the severity of CAD, we analyzed VD in 
all patients, and the non-statin and statin groups (Figure 2). In the non-statin group, PCSK9 levels in 
patients with 1 or 2+3 VD were significantly higher than those in patients with 0 VD (5.20 ± 0.03 vs. 
5.37 ± 0.04 vs. 5.33 ± 0.04, p = 0.003), whereas there was no significant difference between patients 
with 1 VD and 2+3 VD (Figure 2B). In addition, there were no significant differences among 
patients with 0 VD, 1 VD and 2+3 VD in the statin group (Figure 2C). 
Furthermore, to determine the correlation between the Gensini score and PCSK9 levels, we 
performed correlation analyses. PCSK9 levels were not associated with the Gensini score in all 
patients with CAD (|ρ| = 0.072, p = 0.30), or in either the statin (|ρ| = 0.079, p = 0.48) or non-statin 
group (|ρ| = 0.12, p = 0.17). There was no correlation between PCSK9 levels and Agatson score in all 
 10 
 
patients (|ρ| = 0.059, p = 0.24), or in either the statin (|ρ| = 0.007, p = 0.94) or non-statin group (|ρ| = 
0.007, p = 0.91). 
 
Univariable and multivariable logistic regression analysis regarding the association with CAD 
in all patients and the statin and non-statin groups 
Finally, a logistic regression analysis that corrected for independent variables was performed in all 
patients, and the statin and non-statin groups (Table 3). PCSK9 levels, in addition to age, gender, 
BMI, DM and HDL-C were independently associated with the presence of CAD in all patients. 
PCSK9 levels, in addition to age, gender, BMI, HDL-C and LDL-C were also independently 
associated with the presence of CAD in the non-statin group, whereas BMI and DM, but not PCSK9 
levels, were associated with the presence of CAD in the statin group. 
 
Discussion 
This study investigated the associations between plasma PCSK9 levels and the presence of CAD and 
statin treatment, and further evaluated the associations with the severity of CAD. The results 
indicated that PCSK9 levels in patients with CAD were significantly higher than those in patients 
without CAD in the non-statin group, but were not associated with the presence of CAD in the statin 
group. Finally, PCSK9 levels, in addition to age, gender, BMI, DM and HDL-C, were independently 
associated with the presence of CAD by a multivariable analysis. 
 11 
 
Although various trials have evaluated PCSK9 as a biomarker for CAD, the results remain 
controversial [12-14, 24, 25]. The discrepant results are partly due to differences in patient 
characteristics and treatment. Various atherosclerosis imaging studies have been performed to 
investigate the association between PCSK9 levels and cardiovascular disease, such as carotid intima-
media wall thickness, coronary artery calcium, and the severity of coronary artery disease [11, 25, 
26]. The use of statins leads to an increase in the PCSK9 level due to an increase in its expression in 
hepatocytes [27, 28]. It has been reported that statin increased the activity of sterol regulatory 
element-binding protein-2 [29]. Therefore, we examined the association between PCSK9 levels and 
CAD depending on the presence or absence of statin treatment. A previous retrospective cohort study 
reported that the PCSK9 level was associated with the incidence of CVD [15]. Some reports have 
mentioned that PCSK9 levels were elevated by statin use, and the levels without statin were 
associated with coronary atherosclerosis [30, 31]. In the present study, although subjects were 
enrolled consecutively, including DL, the PCSK9 levels in CAD patients in the non-statin group 
were significantly higher than those in non-CAD subjects, which was consistent with the results in 
previous studies noted above. Finally, we could find that the PCSK9 levels were independently 
associated with the presence of CAD in all patients and in the non-statin group, but not in the statin 
group probably due to changing of PCSK9 levels by statin treatment. 
So far, there have been few studies on the relationship between the PCSK9 level and the 
severity of CAD among populations with a lower incidence of ischemic heart disease, such as in 
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Japanese compared to Western populations. This difference is thought to be due to differences in 
lifestyle and the anatomy of the coronary arteries [32-34]. In the present study, patients with CAD 
had similar levels of LDL-C and non-HDL-C as in previous studies [10-12]. Recent studies have 
suggested that LDL-C or non-HDL-C levels are associated with the severity of coronary 
atherosclerosis [35, 36]. However, unlike these reports, our previous report about the evaluation of 
coronary stenosis in Japanese showed no linear association between LDL-C (non-HDL-C) and the 
Gensini score [19]. In the present study, these cholesterol levels were also nonlinear with respect to 
an increase in the Gensini score (data not shown). The Seven Country Study reported that Japanese 
people have a very low incidence of coronary heart disease compared to Western populations, even 
those with the same cholesterol levels [18]. The incidence of acute myocardial infarction in Japan is 
approximately 25% of that in the United States [37]. With regard to these differences, Japanese tend 
to have a large number of stenotic vessels and a wide range of angiographically diffuse 
atherosclerosis [34]. On the other hand, Caucasians tend to have more severe multi-vessel disease, 
and more severe proximal atherosclerosis. Moreover, regarding the risk factors for CAD, HTN and 
coronary vasoconstriction were related to CAD in Japanese, while cholesterol was strongly related to 
CAD in Caucasians [34, 38]. In this study, patients who were clinically suspected of having CAD or 
who had at least one cardiac risk factor underwent CCTA. This might explain the relatively small 
number of subjects who had a very high Gensini score in this study. Over the past several years, 
many authors have reported that PCSK9 levels are associated with the severity of CAD as assessed 
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by the Gensini score [10-12, 24]. However, there were not significant differences between all of the 
groups. Significant differences were found in comparisons with the high score groups, which had 
much higher Gensini scores than our patients. While the LDL-C and non-HDL-C levels were similar 
to those in these other reports, the Gensini score tended to be considerably lower.  
Thus, our subjects likely had less severe CAD. This suggests that the difference in intermediate 
scores is unimportant from a clinical standpoint. From another point of view, it has been reported 
that PCSK9 levels are not associated with the overall plaque burden or plaque volume, but are 
associated with the necrotic core fraction and volume [39]. On the basis of these considerations, it 
seems plausible that, although PCSK9 levels can predict the presence of CAD, they are not as useful 
for estimating the severity of coronary artery disease. Almontashiri et al. showed that there was no 
association between PCSK9 levels and the number of diseased vessels, except in subjects with acute 
coronary syndrome [30]. An increase in PCSK9 expression leads to the degradation of LDL receptor 
on the liver cell surface and to an increase in LDL-C levels. Moreover, PCSK9 has been found to 
accumulate cholesterol, resulting in the chronic inflammatory process of atherosclerosis by 
enhancing oxidized LDL uptake and the expression of vascular cell adhesion protein-1 [40]. Thus, 
the correlation between PCSK9 levels and cardiovascular events may change with plaque 
progression and plaque characteristics [41]. It could be inferred that it takes a long time for PCSK9 
levels to become correlated with the severity of CAD. As previously described, PCSK9 levels were 
significantly elevated in patients with CAD [41]. Moreover, our findings indicated that PCSK9 levels 
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in a population with relatively low-severity CAD, such as Japanese, are less likely to predict the 
number and severity of diseased vessels. 
This study has several limitations. First, the study was cross-sectional. Both the 1 VD and multi 
VD groups were small. Compared with previous studies, fewer subjects had high-severity stenosis 
[10, 12]. A large number of subjects with a higher Gensini score may be needed to reveal a 
relationship between the PCSK9 level and the severity of CAD. Second, CCTA is not a gold 
standard for the evaluation of CAD, although recent studies have shown that both its sensitivity and 
specificity were approximately 95 % of those for invasive coronary angiography for the 
identification of significant coronary stenosis [42]. Third, calcification were omitted from the 
evaluation. Seventy-seven segments of 24/393 patients (6.1 %) could not be evaluated due to severe 
calcification. Fourth, there were fewer female patients in the multi-vessel disease group. PCSK9 
levels in females have been shown to be significantly higher than those in males [43]. Fifth, the 
patients in the statin group received various types and doses of statin (Supplementary Table 1). 
 
Conclusion 
PCSK9 levels, in addition to age, gender, BMI, HDL-C and LDL-C, were significantly associated 
with the presence of CAD by a multivariable analysis in Japanese patients. However, PCSK9 levels 
were not significantly associated with the severity of CAD. 
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Figure legends 
Figure 1. 
Plasma levels of PCSK9 in all patients and the non-CAD, CAD, non-statin and statin groups (A). 
Plasma levels of PCSK9 in patients with and without CAD in the non-statin (B) and statin (C) 
groups. *p=0.004 vs. the non-CAD group in all patients. #p<0.01 vs. the non-statin group in all 
patients. tp=0.0008 vs. patients without CAD (non-CAD) in the non-statin group. N.S., not 
significant. 
 
Figure 2.  
Plasma levels of PCSK9 in the 0 VD, 1VD and Multi (2+3) VD in all patients (A) and the non-statin 
(B) and statin (C) groups. *p< 0.05 vs. 0 VD. N.S., not significant. 
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Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal 
distribution, the variables are expressed as a median value and interquartile range. CAD, coronary 
artery disease; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia; 
CKD, chronic kidney disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; HbA1c, glycosylated hemoglobin A1c; UA, uric acid; eGFR, estimated 
glomerular filtration rate; PCSK9, pro-protein convertase subtilisin/kexin type 9; ARB, angiotensin II 
receptor blocker; ACE-I, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; BB, 
beta-blocker; DU, diuretic; SU, sulfonylurea; BG, biguanide; DPP4-I, dipeptidyl-peptidase 4 inhibitor. 
 
Table 1. Patient characteristics in all patients, non-CAD and CAD groups. 
 All patients 
(n = 393) 
Non-CAD group 
(n = 182) 
CAD group 
(n = 211) 
P-value 
Non-CAD vs. CAD 
Age, years .66 (59-73) .63 (56-70) .69 (61-75) < .0001 
Sex male, % (n) .51 (202) .45 (82) .57 (120) < 0.019 
BMI, kg/m2 .24 (22-26) .24 (22-26) .23 (21-26) < 0.21 
Family history, % (n) .26 (102) .24 (44) .27 (58) < 0.46 
Smoking, % (n) .38 (149) .33 (60) .42 (89) < 0.061 
HTN, % (n) .72 (283) .63 (115) .80 (168) < 0.0003 
DM, % (n) .23 (89) .16 (29) .28 (60) < 0.003 
DL, % (n) .67 (262) .62 (113) .71 (149) < 0.074 
CKD, % (n) .31 (124) .25 (46) .37 (78) < 0.013 
TG, mg/dl .117 (87-158) .109 (79-154) .124 (94-163) < 0.017 
LDL-C, mg/dl .115 ± 30 .115 ± 30 .114 ± 29 < 0.78 
HDL-C, mg/dl .51 (44-62) .54 (45-66) .50 (43-59) < 0.002 
HbA1c, % (n) 5.7 (5.4-6.2) 5.7 (5.3-6.1) 5.9 (5.5-6.4) < 0.0003 
Fasting glucose, mg/dl .100 (93-113) .99 (93-107) .102 (93-121) < 0.041 
UA, mg/dl 5.4 (4.5-6.3) 5.4 (4.5-6.3) 5.4 (4.5-6.3) < 0.93 
eGFR, ml/min/1.73m2 .67 (57-77) .70 (60-80) .64 (55-75) < 0.002 
PCSK9, ng/ml .213 (169-268) .203 (156-257) .223 (172-278) < 0.006 
Log PCSK9 .5.35 ± 0.36 .5.29 ± 0.39 .5.40 ± 0.33 < 0.004 
Medication     
ARB, % (n) .38 (149) .31 (56) .44 (93) < 0.007 
ACE-I, % (n) .3 (12) .2 (3) .4 (9) < 0.12 
CCB, % (n) .36 (141) .27 (50) .43 (91) < 0.001 
BB, % (n) .11 (43)       .7 (12) .15 (31) < 0.009 
Diuretic, % (n) .10 (41) .9 (17) .11 (24) < 0.51 
Statin, % (n) .34 (134) .27 (50) .40 (84) < 0.01 
SU, % (n) .9 (39) .7 (12) .13 (27) < 0.037 
BG, % (n) .6 (24) .6 (11)       .6 (13) < 0.96 
DPP4-I, % (n) .11 (43) .8 (14) .14 (29) < 0.052 
Continuous variables are expressed as mean  ± SD. When continuous variables did not show a normal 
distribution, the variables are expressed as a median value and interquartile range. CAD, coronary artery 
ease; BMI, body mass index; HTN, hypertension; DM, di betes mellitus; DL, dyslipidemia; CKD, chronic 
kidney di LDL -C, low -dens ty lipoprotein cholesterol; HDL -C, high -density lipoprotein cholesterol; 
HbA1c, glycosylated hemoglobin A1c; UA, uric acid; eGFR, estimated glomerular filtration rate; PCSK9, 
pro-protein convertase subtilisin/kexin ty pe 9 ; ARB, angiotensin II receptor blocker; ACE -I, angiotensin -
converting enzyme inhibitor; CCB, calcium channel blocker; BB, beta-blocker; DU, diuretic; SU, 
sulfonylurea; BG, biguanide; DPP4-I, dipeptidyl-peptidase 4 inhibitor. 
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Table 2. Patient characteristics of all patients, the patients with non-CAD and CAD in the non-statin and statin 
groups. 
 Non-Statin group (n=259)  Statin group (n=134) 
 All patients 
(n=259) 
Non-CAD 
group 
(n = 132) 
CAD 
group 
(n = 127) 
P-value 
Non-CAD 
vs. CAD 
 
All patients 
(n=134) 
Non-CAD 
group 
(n = 50) 
CAD 
 group 
(n = 84) 
P-value 
Non-CAD 
vs. CAD 
Age, years 65 (58-73) 63 (55-70) 69 (60-75) < .0001  67 (60-74) 64 (58-71) 69 (62-75) < 0.059 
Male, % (n) 52 (134) 45 (59) 59 (75) < 0.021  51 (68) 46 (23) 54 (45) < 0.40 
BMI, kg/m2 23 (21-26) 24 (22-26) 23 (21-26) < 0.22  24 (22-26) 24 (22-27) 24 (22-26) < 0.39 
Family history, 
Smoking, % (n) 
24 (63) 25 (33) 24 (30) < 0.80 
 
29 (39) 22 (11) 33 (28) < 0.16 
Smoking, % (n) 39 (102) 33 (44) 46 (58) < 0.042  35 (47) 32 (16) 37 (31) < 0.57 
HTN, % (n) 67 (173) 60 (79) 74 (94) < 0.016  82 (110)** 72 (36) 88 (74) < 0.019 
DM, % (n) 18 (47) 14 (18) 23 (29) < 0.055  31 (42)**
 
22 (11) 37 (31) < 0.072 
DL, % (n) 49 (128) 48 (63) 51 (65) < 0.58  100 (134)** 100 100  
CKD, % (n) 31 (79) 24 (32) 37 (47) < 0.026  34 (45) 26 (13) 37 (31) < 0.19 
TG, mg/dl 
117  
(87-158) 
108  
(79-154) 
125  
(96-162) 
< 0.042 
 
117 (90-163) 
112  
(78-156) 
124  
(93-166) 
< 0.16 
LDL-C, mg/dl 119 ± 30 117 ± 27 120 ± 32 < 0.362  107 ± 27** 110 ± 35 104 ± 23 < 0.27 
HDL-C, mg/dl 51 (44-63) 53 (45-68) 49 (42-58) < 0.005  52 (45-62) 54 (47-62) 51 (44-61) < 0.31 
HbA1c, % 
5.7  
(5.3-6.2) 
5.6  
(5.3-6.0) 
5.8  
(5.5-6.3) 
< 0.002 
 5.9  
(5.5-6.5)**
 
5.8  
(5.6-6.3) 
5.9  
(5.5-6.8) 
< 0.19 
Fasting glucose, 
mg/dl 
100  
(93-112) 
100  
(94-108) 
102  
(93-118) 
< 0.19 
 99  
(93-116) 
98  
(92-105) 
102  
(93-127) 
< 0.089 
UA, mg/dl 
5.4  
(4.5-6.2) 
5.3  
(4.5-6.2) 
5.4  
(4.5-6.3) 
< 0.61 
 5.6  
(4.5-6.5) 
5.7  
(4.5-7.8) 
5.5  
(4.5-6.3) 
< 0.22 
eGFR, 
ml/min/1.73m2 
68 (57-78) 70 (61-82) 65 (55-76) < 0.019 
 
64 (57-75) 68 (59-77) 64 (55-73) < 0.064 
PCSK9, ng/ml 
196 
（159-247） 
182 
（150-235） 
213 
（169-261） 
< 0.003  
252 
（201-303）** 
252 
（210-294） 
253 
（197-304） 
< 0.67 
Log PCSK9 
5.28  
± 0.34 
5.21  
± 0.36 
5.35  
± 0.31 
< 0.0008 
 5.49  
± 0.37** 
5.51  
± 0.40 
5.47  
± 0.34 
< 0.51 
CAD, % (n) 49 (127)     63 (84)*    
VD 0  100 (132) 0    100 0  
VD 1  0 45 (57)    0 32 (27)  
VD 2+3  0 55 (70)    0 68 (57)  
Gensini score  2.5 (0-6) 15 (10-23) < .0001   2.5 (0-6) 18 (13-27) < .0001 
Medication          
ARB, % (n) 29 (76) .26 (33) 34 (43) < 0.12  54 (73)** .46 (23) 60 (50) < 0.13 
ACE-I, % (n) 2 (3) .2 (2) 2 (3) < 0.62  5 (7) .2 (1) 7 (6) < 0.17 
CCB, % (n) 31 (81) .23 (30) 40 (51) < 0.002  45 (60)** .40 (20) 48 (40) < 0.39 
BB, % (n) 8 (22) .7 (9) 10 (13) < 0.32  16 (21)* .6 (3) 21 (18) < 0.012 
Diuretic, % (n) 10 (27) .11 (14) 10 (13) < 0.92  10 (14) .6 (3) 13 (11) < 0.18 
SU, % (n) 7 (19) .6 (8) 9 (11) < 0.42  15 (20) .8 (4) 19 (16) < 0.071 
BG, % (n) 4 (11) .5 (6) 4 (5) < 0.81  10 (13) .10 (5) 10 (8) < 0.93 
DPP4-I, % (n) 9 (23) .8 (10) 10 (13) < 0.45  15 (20) .8 (4) 19 (16) < 0.071 
Continuous variables are expressed as mean ± SD. When continuous variables did not show a normal 
distribution, the variables are expressed as a median value and interquartile range. CAD, coronary artery 
disease; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; DL, dyslipidemia; CKD, 
chronic kidney disease; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; HbA1c, glycosylated hemoglobin A1c; UA, uric acid; eGFR, estimated glomerular filtration 
rate; PCSK9, pro-protein convertase subtilisin/kexin type 9; VD, vessel disease (the number of significantly 
stenosed coronary vessels); ARB, angiotensin II receptor blocker; ACE-I, angiotensin-converting enzyme 
inhibitor; CCB, calcium channel blocker; BB, beta-blocker; DU, diuretic; SU, sulfonylurea; BG, biguanide; 
DPP4-I, dipeptidyl-peptidase 4 inhibitor. *p < 0.05 vs. all patients in the non-statin group. **p < 0.01 vs. all 
patients in the non-statin group. 
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Table 3. The univariable and multivariable logistic regression analysis regarding the association with CAD in 
all patients, the statin and non-statin groups. 
 
CAD, coronary artery disease; OR, odds ratio; CI, confidence Interval; BMI, body mass index; HTN, 
hypertension; DM, diabetes mellitus; CKD, chronic kidney disease; PCSK9, pro-protein convertase 
subtilisin/kexin type 9; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol. 
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Supplementary table. Types and doses of statin in the statin group. 
Types  All, n (%) CAD, n (%) Non-CAD, n (%) 
atorvastatin  39 (100) 28 (100) 11 (100) 
 5 mg/day 14 (36) 10 (36) 4 (36) 
 10 mg/day 25 (64) 18 (64) 7 (64) 
     
pravastatin  19 (100) 13 (100) 6 (100) 
 5 mg/day 6 (32) 3 (23) 3 (50) 
 10 mg/day 13 (68) 10 (77) 3 (50) 
     
pitavastatin  31 (100)   
 1 mg/day 17 (55) 12 (55) 5 (56) 
 2 mg/day 12 (39) 9 (41) 3 (33) 
 4 mg/day 2 (6) 1 (5) 1 (11) 
     
fluvastatin  2 (100) 1 (100) 1 (100) 
 20 mg/day 1 (50) 0 1 (100) 
 30 mg/day 1 (50) 1 (100) 0 
     
rosvastatin  36 (100) 17 (100) 19 (100) 
 2.5 mg/day 19 (53) 7 (41) 12 (63) 
 5 mg/day 13 (36) 7 (41) 6 (32) 
 7.5 mg/day 2 (6) 2 (12) 0 
 10 mg/day 1 (3) 1 (6) 0 
 Unknown 1 (3) 0 1 (5) 
     
simvastatin     
 5 mg/day 5 3 2 
     
unknown  2   
CAD, coronary artery disease. 
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